The reasons for the difference between the U.S. and Canada, in terms of the IFAH report you're talking about, have been because we have had a backlog, but processes have been put in place.
The registration system in the U.S. is a little different from the one in Canada, in that throughout drug development you have a system whereby companies will be interacting with the U.S. at all stages during the process. We haven't implemented a process like that. We are beginning to implement that process so we can be on a par with the way the system works in the U.S.